Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 3Endometrial Neoplasms 3Neoplasm Metastasis 2Carcinosarcoma 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Salivary Gland Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms by Site 1Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Lung Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Endometrioid 1

Interventions

pembrolizumab 15Nivolumab 10avelumab 9atezolizumab 8Gemcitabine 8Cisplatin 8Magnetic Resonance Spectroscopy 6durvalumab 5Specimen Handling 5Docetaxel 5Carboplatin 5Paclitaxel 4Ipilimumab 4tislelizumab 3sacituzumab govitecan 3enfortumab vedotin 3Taxes 3Pemetrexed 3Mitomycin 3eribulin 2erdafitinib 2cabozantinib 2Doxorubicin 2CTLA-4 Antigen 2ALT-803 2zimberelimab 1veliparib 1urelumab 1tazemetostat 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Transitional Cell × ceralasertib × Clear all
NCT03682289 2026-04-23

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

University of California, San Francisco

Phase 2 Active not recruiting
83 enrolled
GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡